Hemophilia A With Inhibitors Clinical Trial
Official title:
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
The purpose of the study is to assess the safety, efficacy and pharmacokinetics of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00231751 -
The Malmö International Brother Study (MIBS)
|
N/A | |
Completed |
NCT00221195 -
Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
|
Phase 2/Phase 3 | |
Terminated |
NCT02484638 -
Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors
|
Phase 2/Phase 3 | |
Terminated |
NCT00212472 -
International Immune Tolerance Study
|
N/A | |
Withdrawn |
NCT03002480 -
Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography
|
N/A | |
Completed |
NCT03093480 -
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
|
Phase 4 | |
Completed |
NCT02448680 -
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa
|
Phase 3 | |
Active, not recruiting |
NCT01105546 -
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
|
Phase 2 |